Development of IgG Mediated Antibody Dependent Cell-mediated Cytotoxicity (ADCC) in the Serum and Genital Mucosa of HIV Seroconverters.

Autor:	Aziz M; CORE Center, Cook County Health and Hospitals System, Chicago, IL 60612, USA; Division of Infectious Diseases, Rush University Medical Center, Chicago, IL, 60612, USA., Mahmood F; Department of Immunology/Microbiology Rush University Medical Center, Chicago, IL, 60612, USA., Mata M; Department of Immunology/Microbiology Rush University Medical Center, Chicago, IL, 60612, USA., Durkin HG; SUNY Downstate Medical Center, Brooklyn, NY, 11203, USA., Liu C; Georgetown University, Washington, DC, 20057, USA., Greenblatt RM; University of California, San Francisco, CA, 94110 USA., Nowicki M; University of Southern California Norris Hospital, Los Angeles, CA, 90033 USA., Golub ET; Johns Hopkins University, Baltimore, MD 21218, USA., Anastos K; Montefiore Medical Center, Bronx, NY, 10467 USA., French AL; CORE Center, Cook County Health and Hospitals System, Chicago, IL 60612, USA; Division of Infectious Diseases, Rush University Medical Center, Chicago, IL, 60612, USA., Baum LL; Department of Immunology/Microbiology Rush University Medical Center, Chicago, IL, 60612, USA.
Jazyk:	angličtina
Zdroj:	Journal of AIDS & clinical research [J AIDS Clin Res] 2015 Jul; Vol. 6 (7). Date of Electronic Publication: 2015 Jul 09.
DOI:	10.4172/2155-6113.1000479
Abstrakt:	Background: We measured antibody-dependent cell mediated cytotoxicity (ADCC) activity in serum and genital fluids of heterosexually exposed women during HIV seroconversion. Methods: Plasma and cervico-vaginal lavage (CVL) fluid from 11 seroconverters (SC) were analyzed biannually from one year pre- to 6 year post-seroconversion using a 51 Cr-release assay to measure HIV-1 gp120 specific ADCC. Results: No SC had significant HIV specific CVL ADCC activity before seroconversion or until 1.5 yr after seroconversion. One individual had a %Specific Release (SR) of 25.4 at 2 years, 26.7 at 3 years and 21.0 at 4 years after seroconversion in CVL. Another sample had 4.7% SR at 2 years, 5.3 at 3 years, 10.9 at 4 years, and 8.4 at 5 years after seroconversion in CVL. A third had no activity until 17% SR 5 years after seroconversion in CVL. A fourth showed activity of 36.5% SR at 6.5 years after seroconversion. Seven women had no ADCC activity in their CVL. Paired serum samples showed HIV specific ADCC activity prior to the appearance of CVL ADCC activity. Conclusions: HIV specific ADCC activity in CVL rose 2 years after seroconversion; ADCC was present in the serum prior to this time. These data suggest that genital tract ADCC activity is not present until well after acute infection.
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu